Menlo Park, California, October 1, 2012. 3‐V Biosciences, Inc., announced today that two abstracts have been accepted for presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 9‐13 in Boston, Massachusetts.
3‐V Biosciences is discovering and developing oral antiviral therapeutics designed to have broad-spectrum activity and a high barrier to resistance. Data characterizing the preclinical antiviral activity of the company’s novel small molecules targeting the fatty acid synthase (FASN) pathway for the potential treatment of chronic hepatitis C virus (HCV) infection will be featured in oral and poster presentations.
Oral Presentation
Sunday, November 11, 2012 at 5:30pm ET:
HCV Therapy: Preclinical and Early Clinical Development
“Potent Hepatitis C Antiviral Activity By Inhibiting Fatty Acid Synthase” (Parallel 13, Hynes: Room 21)
Poster Presentation (Presidential Poster of Distinction award)
Tuesday, November 13, 2012 from 8:00am ‐ 12:00pm ET:
HCV Therapy: Preclinical and Early Clinical Development
“TV‐2640, a Novel Anti‐HCV Agent, Safely Causes Sustained Host‐Target Inhibition in Vivo” (Poster Hall, #1876)
About FASN
FASN is a cellular enzyme implicated in HCV replication and several cancers. First‐generation FASN inhibitors have shown preclinical benefits in a variety of viral infections, including HCV, as well as in models of pancreatic, prostatic, breast and colorectal tumors, but their development has been hindered by poor bioavailability and systemic tolerability. 3‐V has discovered and is advancing proprietary FASN inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, and have the potential to become potent therapeutics for chronic HCV and other indications.
About 3-V Biosciences
3‐V Biosciences, Inc. is a privately held biopharmaceutical company that discovers and develops antiviral therapeutics designed to have broad-spectrum activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3‐V team applies an integrated approach with internal expertise in virology, biology, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.
For additional information on 3-V Biosciences, please visit www.3vbio.com.com.
Contact information
Stephen R. Brady Chief Business Officer 650‐561‐8600
Media Inquiries
BCC Partners on behalf of 3-‐V Biosciences, Inc. Karen L. Bergman
650-‐575-‐1509
kbergman@bccpartners.com
Michelle Corral 415-‐794-‐8662 mcorral@bccpartners.com
